Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track ACRV with free AI briefings, catalyst countdowns, and dilution alerts.

ACRV — Acrivon Therapeutics, Inc.

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$41.5M Cash on Hand

20.4mo Cash Runway

20% Short Interest

🧪 Upcoming Trial Catalysts

2026-08-12 · Phase 1 — Recruiting — Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
2026-10-31 · Phase 2 — Recruiting — A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
2028-08-23 · Phase 2 — Recruiting — A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

📊 Drug Pipeline

Drug	Indication	Phase	Status
ACR-368	Head and Neck Squamous Cell Carcinoma	PHASE2	RECRUITING
Gemcitabine	Head and Neck Squamous Cell Carcinoma	PHASE2	RECRUITING
ACR-2316	Specific Advanced Solid Tumors	PHASE1	RECRUITING

💰 Cash Runway & Dilution Risk

ACRV holds $41.5M in cash and burns about $6.1M/quarter from operations, giving an estimated runway of 20.4 months. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for ACRV free →

📈 Recent Insider Activity (Form 4)

Date	Insider	Type	Value
2026-03-03	Mirza Mansoor Raza	Purchase	$0
2026-03-03	Devroe Eric	Purchase	$0
2026-03-03	Gamelin Erick	Purchase	$0
2026-03-03	Miller Mary	Purchase	$0
2026-03-03	Peterson Katharine	Purchase	$0

Get the full ACRV picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for ACRV and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z